SCHEMBL4152867

SCHEMBL4152867

CN(C)C(=O)c1ccc(N2CCC[C@H](NC(=O)C34CC5CC(C3)C(O)C(C5)C4)C2)nc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BTK Q06187 9/20 0.46
LCK P06239 7/20 0.46
JAK3 P52333 7/20 0.46
EGFR P00533 4/20 0.46
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
MEN1 O00255 1/20 0.38
HSD11B1 P28845 5/20 0.37
HSD11B2 P80365 4/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ADRA1A P35348 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010733 0.89 KMT2A (0.45) BTKKMT2AHSD17B10HRH3MEN1
SCHEMBL4142418 0.87 KMT2A (0.43) KMT2AMEN1HSD11B1HSD11B2
SCHEMBL4005054 0.85 HSD11B1 (0.40) KMT2AMEN1HSD11B1HSD11B2
SCHEMBL4011662 0.85 KMT2A (0.42) BTKKMT2AMEN1HSD11B1HSD11B2
SCHEMBL5950733 0.85 HSD11B1 (0.40) KMT2AMEN1HSD11B1HSD11B2
SCHEMBL3999588 0.85 KMT2A (0.42) BTKKMT2AMEN1HSD11B1HSD11B2
SCHEMBL5950770 0.85 GRM1 (0.50) KMT2AMEN1HSD11B1HSD11B2
SCHEMBL4003557 0.85 GRM1 (0.50) KMT2AMEN1HSD11B1HSD11B2
SCHEMBL4002511 0.84 KMT2A (0.47) BTKLCKJAK3KMT2AMEN1
SCHEMBL4002517 0.84 KMT2A (0.47) BTKLCKJAK3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP claimed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 BTK 2479/4885LCK 4660/4885JAK3 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.